Browse the full management transaction log of Prothena Corp plc, a publicly traded company based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Market capitalisation: €493.2m. The latest transaction was filed on 15 January 2016 (Levée d'options). Among the most active insiders: Walker Karin L. The full history is free.
10
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
7 ops.
Sell Volume
11Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
600 sharesOrdinary Shares, par value $0.01 per shareSEC:0000899243-16-011134:3
10 of 10 declarations
About Prothena Corp plc
Prothena Corp plc is a biopharmaceutical company focused on the discovery and development of therapies for neurodegenerative diseases. It is listed on NASDAQ under the ticker PRTA.